Intriguingly, TRPM2 has been shown to be the primary mediator of ROS-dependent BBB degradation in several brain disorders (Ding et al., 2021), including ischemic stroke (Zong et al., 2024) and Alzheimer’s disease (Park et al., 2014). The gene discussed is TRPM2; the disease is early-onset autosomal dominant Alzheimer disease.